MORC3 and COVID-19: [34] also reported development of anti-NXP2 dermatomyositis following Comirnaty COVID-19 vaccination, and an initial presentation of myalgia, crusted eruptions, and also elevated CPK levels, which was eventually treated with pulsed intravenous methylprednisolone followed by 1 mg/kg prednisolone.